What is step therapy for CGRP drugs?

It is a payer rule that requires you to try and fail cheaper, older preventives first, often two of them, before your plan will cover a CGRP monoclonal antibody or a preventive gepant. The failures usually have to be documented in your chart before the prior-authorization is approved.

Why does the postdrome matter for a prior-auth appeal?

Prior-auth forms count headache days but not the 24 to 72 hour after-phase of fatigue, brain fog, and residual photophobia. That recovery tail is where much of the real disability sits, so documenting it with a dated timeline gives a reviewer disability they have to account for instead of headache days they can round down.

What documentation strengthens a CGRP coverage appeal?

A continuous, timestamped record: attack onset, acute medication and timing, symptom resolution, and the postdrome tail with its own end date. A log that shows the whole arc, plus the older preventives you tried and how they affected you, is harder to deny than a bare frequency count.

The CGRP prior-auth squeeze and the after-phase no form asks about

Article · 3 min read

The prior-auth form never asks how long the fog lasts.

Q: Does this policy change apply to my plan?

Not necessarily. Final CMS prior authorization regulations apply to Medicare Advantage, Marketplace, Medicaid, and other plans, not commercial plans only. ([source](https://www.kff.org/private-insurance/final-prior-authorization-rules-look-to-streamline-the-process-but-issues-remain/)) Payer rules differ by plan and state, so confirm against your own formulary and plan documents before assuming the change affects your coverage.

A fresh payer policy change puts CGRP access back in the spotlight. Here is what it means for the after-phase your appeal never documents.

What changed this week

A payer policy update landed on A CGRP article covering first-line status and a Raynaud safety signal was published on July 17, 2026. ([source](https://www.medscape.com/c99/p10/cgrp-therapies-are-now-first-line-migraine-and-so-raynaud-2026a1000o6o)): Postdrome's Pro insurance prior-authorization export is built around the CGRP biologic approval criteria used by UnitedHealthcare, Cigna, Kaiser Permanente, and Blue Cross Blue Shield, the four major insurers most commonly involved in CGRP prior-auth denials for migraine patients. The American Headache Society's updated position statement now designates CGRP-targeting therapies a first-line option for migraine prevention. ([source](https://www.medscape.com/c99/p10/cgrp-therapies-are-now-first-line-migraine-and-so-raynaud-2026a1000o6o)).

For anyone on a CGRP preventive, or fighting to get onto one, the mechanics matter more than the headline. The class covers the monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) and the gepants used for prevention (atogepant, rimegepant). A taller gate on any of them means more paperwork, another appeal, and time lost while the attacks keep arriving.

Weeks of waiting. That is the real cost, and it is the part the announcement never quantifies. Source: UHC's PA-Notification for CGRP receptor antagonists is publicly available at uhcprovider.com, announcing an updated initial authorization duration of 12 months. ([source](https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/a-g/PA-Notification-CGRP-Receptor-Antagonists.pdf)).

The after-phase blind spot

Every prior-authorization form asks the same short list: monthly headache days, which older preventives you failed, your diagnosis code. None of them ask how long you were unusable after the pain stopped.

Call it the after-phase blind spot. The postdrome, that 24 to 72 hours of fatigue, brain fog, residual photophobia, and flattened mood, is where a large share of the real disability lives, and it is invisible to the exact document deciding whether you get the drug. A payer counting your headache days is undercounting your disabled days by design.

You are not counting headache days. You are counting the days migraine took.

Why 'fail two preventives first' misses the point

Step therapy assumes the older options, the beta-blockers, the topiramate, the amitriptyline, are interchangeable first drafts of the CGRP drugs. They are not. They were built for a different mechanism, and their side-effect load, the cognitive dulling from topiramate especially, can deepen the very fog the postdrome already brings.

Requiring two documented failures before covering a targeted preventive is not a safety step. It is a cost-delay tactic, and the delay is measured in attacks you did not have to have.

What the appeal actually needs to show

Here is what makes a denial harder to write: a continuous timeline that captures the attack and everything after it. Not a tally of 'bad days' but a dated record, attack onset, medication taken and when, symptom resolution, and then the postdrome tail with its own end date.

When a form asks for headache frequency and you answer with a timestamped log that also documents the recovery window, the reviewer has less room to shrink a debilitating month into four tidy 'headache days.' The recovery tail stops being a feeling you describe and becomes data they have to account for.

Standard CGRP prior-auth fields against the after-phase symptoms they never record.
What the prior-auth form asks	What it leaves out
Monthly headache days	How many days the postdrome fog lasted
Prior preventives failed	Whether topiramate deepened the cognitive fog
Diagnosis / ICD code	Residual photophobia after the pain resolved
Acute meds used per month	Mood and function during the recovery tail

Check your own plan documents

Payer policies vary by plan and by state. Final CMS prior authorization regulations apply to Medicare Advantage, Marketplace, Medicaid, and other plans, not commercial plans only. ([source](https://www.kff.org/private-insurance/final-prior-authorization-rules-look-to-streamline-the-process-but-issues-remain/)), confirm against your own formulary before assuming it hits you.

Where a continuous log changes the math

This is the gap Postdrome was built around. It tracks the whole arc rather than just the headache: aura, attack, medication, and the postdrome tail, on one continuous timeline you can export.

The free CGRP Prior-Auth Letter Builder turns that record into the documentation an appeal needs, in the payer's own vocabulary, so the recovery window shows up where a reviewer has to read it. Lifetime pricing, on-device, no subscription standing between you and your own health data.

What we're tracking next

Payer policies on the CGRP class move quietly and often. We are watching the next wave of step-therapy changes across major payers and PBMs, and whether any form, anywhere, starts asking about recovery time at all.

Until one does, the burden of proving the after-phase stays where it always has: on you. The least a tracker can do is make that proof easy to produce on a day when you can barely see the screen.

Track the whole arc, attack through after-phase, and export the record your appeal needs.

Postdrome is built for the reader who already knows what the postdrome is, because the people who built it watched the after-phase go undocumented in every app they tried. The continuous timeline and the CGRP Prior-Auth Letter Builder exist for exactly this moment: when the paperwork asks for headache days and your disability lives in the recovery tail.

Get Postdrome